medigraphic.com
ISSN 2594-1526 (Digital)
ISSN 0028-3746 (Impreso)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2006, Número S1

<< Anterior Siguiente >>

Neumol Cir Torax 2006; 65 (S1)


Instrumentos de calidad de vida en el paciente con enfermedad pulmonar obstructiva crónica (EPOC)

López VMV

Idioma: Español
Referencias bibliográficas: 34
Paginas: 11-16
Archivo PDF: 52.01 Kb.


RESUMEN

La calidad de vida relacionada con la salud permite evaluar la repercusión de una enfermedad crónica sobre el individuo y los resultados del tratamiento de la misma. Existen instrumentos genéricos y específicos para evaluar la calidad de vida en los pacientes con EPOC. Los cuestionarios genéricos han sido diseñados para evaluar pacientes con un amplio espectro de enfermedad y pueden ser menos sensibles que los específicos cuyo contenido está dirigido a los aspectos relevantes sobre los que impacta la enfermedad en cuestión. En este capítulo revisaremos los cuestionarios genéricos y específicos para pacientes con enfermedad respiratoria de uso más frecuente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Patrick DL, Erickson P. Assessing health-related quality of life for clinical decision making. In: Walker S, Rosser R, eds. Quality of Life Assessment: Key Issues in the 1990s. Boston: Kluwer, 1993: 11-63.

  2. Jones PW. Dyspnea and quality of life in chronic obstructive pulmonary disease. In: Mahler D, ed. Dyspnea. New York: Marcel Dekker, Inc., 1997: 199-220.

  3. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.

  4. Engström CP, Persson LO, Larsson S, Sullivan M. Healthrelated quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001; 18: 69-76.

  5. ATS/ACCP Statement of Cardiopulmonar Exercise Testing. Am Respir Crit Care Med 2003; 167: 211-277.

  6. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care 1992; 30: 473-483.

  7. Alonso J, Prieto L, Anto JM. La versión española del SF- 36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc). 1995; 104: 771-776.

  8. Sanjuás BC. Medición de la calidad de vida: ¿cuestionarios genéricos o específicos? Arch Bronconeumol 2005; 41: 107-109.

  9. Desikan R, Mason HL, Rupp MT, Skehan M. Health-related quality of life and healthcare resource utilization by COPD patients: a comparison of three instruments. Qual Life Res 2002; 11: 739-751.

  10. Spencer S, Carverley PMA, Burge PS, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122-128.

  11. Griffiths TL, Ionescu A, Mullins J, Turner-Lawlor P, Thomas J, Burr M. Use of the SF-36 questionnaire as an outcome measure in a randomized controlled trial of pulmonary rehabilitation. Am J Respir Crit Care Med 1998; 157: A257.

  12. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to score Version 2 of SF-12 Health Survey. Qualitymetric Incorporated. Lincoln, Rhode Island and Health Assessment Lab. Boston, Massachusetts. October 2002.

  13. Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal P, Victora CG. PLATINO Team. Chronic Obstructive Pulmonary Disease in five Latin American cities (the PLATINO Study): a prevalence study. Lancet 2005; 366: 1875-1881.

  14. Bergner M, Bobbitt R, Pollard WE, Martin DP, Gilson BS. The sickness impact profile: validation of a health status measure. Med Care 1976; 14: 57-67.

  15. Badía X, Alonso J. Adaptación de una medida de la disfunción relacionada con la enfermedad: la version española del Sickness Impact Profile. Med Clin (Barc) 1994; 102: 90-95.

  16. Jones PW, Baveystock CM, Littlejohns P. Relationships between general health measured with the sickness impact profile and respiratory symptoms, physiological measures and mood in patients with chronic airflow limitation. Am Rev Respir Dis 1989; 140: 1538-1543.

  17. Bergner M, Hudson LD, Conrad DA, Patmont CM, Mc-Donald GJ, Perrin EB, Wilson BS. The cost and efficacy of home care for patients with chronic lung disease. Med Care 1988; 26: 566-579.

  18. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Ann Intern Med 1980; 93: 391-398.

  19. Hunt SM, Mc Kenna SP, Mc Ewen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981; 15a: 221-229.

  20. Alonso J, Antó JM, Moreno C. Spanish version of the Nottingham health profile: translation and preliminary validity. AJPH 1990; 80: 704-708.

  21. Jaeschke R, SingerJ, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.

  22. Guell R, Casan P, Sangenis M, Santis J, Morante F, Borras JM, Guyatt G. The Spanish translation and evaluation of quality of life questionnaire in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 1995; 31: 202-210.

  23. Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996; 348: 1115-1119.

  24. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Ionescu AA, Thomas J, Tunbridge J. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 2000; 355: 362-368.

  25. Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P, Ramsdale H, Jaeschke R, Sears M. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 85-90.

  26. Bourbeau J, Rouleau MY, Boucher S. Randomized controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 477-482.

  27. Jones PW. Quality of life measurements for patients with diseases of the airways. Thorax 1991; 46: 676-682.

  28. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404.

  29. Ferrer M, Alonso J, Prieto L, Plaza V, Monso E, Marrades R, Aguar MC, Khalaf A, Anto JM. Validity and reliability of the St. George´s Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J 1996; 9: 1160-1166.

  30. Jones PW, Bosh TK. Quality of life in COPD patients treated with salmeterol. Am J Resp Crit Care Med 1997; 155: 1283-1289

  31. Dahl R, Greefhorst LAPM, Nowak D, Nonikov V, Byme AM, Thomson MH, Till D, Della-Cioppa G. Formoterol in chronic obstructive pulmonary disease I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2001; 164: 778-784.

  32. Vincken W, van Noord JA, Greeforst AP, Bantje TA, Kesten S, Korducki L, Comelissen PJ. Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1year´s treatment with tiotropium. Eur Respir J 2002; 19: 209-216.

  33. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A longterm evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.

  34. Burge PS, Carverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.




2020     |     www.medigraphic.com